Cargando…
The Cost-effectiveness of Celecoxib versus Non-steroidal Anti-inflammatory Drugs plus Proton-pump Inhibitors for Treating Osteoarthritis in Algeria
Background: Cyclooxygenase-2 inhibitors such as celecoxib are as effective as non-selective non-steroidal anti-inflammatory drugs (ns-NSAIDs) in the treatment of osteoarthritis (OA), have fewer gastrointestinal side effects, but are more expensive. Objective: To evaluate the incremental cost-effecti...
Autores principales: | Hammoumraoui, Nadir, Kherraf, Sid Ahmed, Mould-Quevedo, Joaquin, Ismail, Tarek A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Columbia Data Analytics, LLC
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471414/ https://www.ncbi.nlm.nih.gov/pubmed/37662022 |
Ejemplares similares
-
The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia
por: Nasef, Sherif A, et al.
Publicado: (2015) -
Comparing the Fiscal Consequences of Controlled and Uncontrolled Osteoarthritis Pain Applying a UK Public Economic Perspective
por: Martins, Rui, et al.
Publicado: (2021) -
A novel monoclonal antibody with improved FcγR blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose
por: Nakajima-Kato, Yuko, et al.
Publicado: (2022) -
A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models
por: Cho, Somi, et al.
Publicado: (2022) -
Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response
por: Valli, Atte, et al.
Publicado: (2022)